Akesobio
China - Zhongshan
BiotechnologyFocus: Antibody Therapies
Akesobio is a life sciences company focused on Antibody Therapies.
Oncology
Funding Stage
PUBLIC
Open Jobs
1
Products & Portfolio (1)
Pipeline & Clinical Trials
AK120 or placebo- Part 1- Cohort 1
Atopic DermatitisClinical Trials (1)
NCT04256174A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis
Phase 1AK117
Neoplasms MalignantClinical Trials (1)
NCT04349969A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104
Phase 1AK112
Neoplasms MalignantClinical Trials (1)
NCT04047290A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT05021120A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
Phase 1AK-104
Advanced CancerClinical Trials (1)
NCT03261011Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT04516564A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
Phase 1AK-105
Advanced CancerClinical Trials (1)
NCT03352531Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Phase 1AK111 or Placebo
PsoriasisClinical Trials (1)
NCT03622021A Study of AK111 in Healthy Subjects
Phase 1Phase 1/2
Clinical Trials (1)
NCT07208773A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Phase 1/2Phase 2
Clinical Trials (1)
NCT06187961Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase 2Ivonescimab
Metastatic Colorectal CancerClinical Trials (1)
NCT06959550Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
Phase 2Chidamide in combination with Ivonescimab
Non-Small Cell Lung CancerClinical Trials (1)
NCT07412262A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression
Phase 2Phase 2
Clinical Trials (1)
NCT04380805A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Phase 2Placebo
Atopic DermatitisClinical Trials (1)
NCT05048056Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
Phase 2Ivonescimab
Pancreatic CancerClinical Trials (1)
NCT06491472Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
Phase 2Ligufalimab
Advanced Hepatocellular CarcinomaClinical Trials (1)
NCT06789848Ligufalimab and Cadonilimab in Advanced Liver Cancers
Phase 2Cadonilimab Combined with chemotherapy
Pleural MesotheliomaClinical Trials (1)
NCT06416930Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Phase 2IBI351+AK112
KRAS G12C Lung CancerClinical Trials (1)
NCT06936644A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation
Phase 2standard EBRT+Brachytherapy
Locally Advanced Cervical CarcinomaClinical Trials (1)
NCT07400536A Clinical Study on the Treatment of LACC With Cadonilimab Combined With Chemotherapy Followed by CCRT
Phase 3Open Jobs (1)
Interview Prep Quick Facts
Founded: 2012
Portfolio: 1 approved product, 19 clinical trials
Top TAs: Oncology
Open Roles: 1 active job
Portfolio Health
Peak1 (100%)
1 total products